CDKN1A and glioblastoma: Enhanced p53 expression, MDM-2 degradation, reduced Cdc25C, increased cyclin dependent kinase inhibitor 1A, (CDKN1A, p21Cip1/Waf1), and increased p-Cdk1 induced G2/M arrest in glioblastoma tumors after 1 week of DATS treatment [63].